A group of medical researchers have recently claimed that using stem cell transplantation to treat patients with a serious but a very rare form of chronic blood cancer 'Juvenile Myelomonocytic Leukemia' (JMML) has shown improved results.
Researchers at the Children's Hospital Los Angeles (CHLA), led by Dr. Hisham Abdel-Azim, looked at the children with Juvenile Myelomonocytic Leukemia (JMML) who underwent cell transplantation at the hospital and noticed that all of them were alive and in clinical remission.
Abdel-Azim said that the lack of transplant-related mortality in the group of children we studied at the Children's Center for Cancer and Blood Diseases at the hospital suggested that BUMEL (Intravenous Busulfan and Melphalan) may represent a successful cell transplantation high-dose chemotherapy regimen.
He said that it was also possible that administering conventional dose chemotherapy, before cell transplantation, to patients with more progressive disease may have contributed to improved outcomes.
He added that a follow up clinical trial was warranted to confirm these promising findings.
The study has been published in the journal Blood.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
